Abstract

COMPARISON OF CLINICAL OUTCOMES AND SAFETY PROFILES OF ETORICOXIB AND NAPROXEN IN OSTEOARTHRITIS PATIENTS: A REVIEW

Vinochandar R.*, Gokul P., Vimal Raj S., Dineskumar S., Leo Albert S., Sowmiya A. and Jeevitha D.

ABSTRACT

Osteoarthritis (OA), also called osteoarthrosis or degenerative joint disease (DJD), is the most common form chronic synovial joint disorder. It is characterized by progressive degenerative changes in the articular cartilage over the years, especially in weight-bearing joints. Etoricoxib is an NSAID that belongs to the category of selective COX-2 inhibitors. It has the greatest selectivity for COX-2 and can manage the pain and inflammation associated with osteoarthritis. It is described once a daily at a rate of 30 to 90 mg, to be taken with or without food. Etoricoxib is used to treat arthritis, acute rheumatoid arthritis / gout, ankylosing spondylitis, dysmenorrhea, acute pain associated with dental surgery, and other similar conditions without affecting the function of platelets in the gastric mucosa, and its effectiveness is monitored. Naproxen is an NSAID, which belongs to the category of non-selective COX inhibitors. As an NSAID, naproxen appears to exert its anti-inflammatory action by reducing the production of inflammatory mediators called prostaglandins. It is metabolized by the liver to inactive metabolites. Naproxen's anti-inflammatory properties can relieve pain caused by inflammatory conditions, such as migraines, kidney stones, psoriatic arthritis, and menstrual cramps. The usual dose of naproxen for osteoarthritis is 250 to 500 mg twice a day. Etoricoxib is for gastrointestinal problems and naproxen has a lower cardiovascular risk. Finally, comparing the safety and effectiveness of etoricoxib and naproxen, etoricoxib has better safety and efficacy in the treatment of osteoarthritis. Etoricoxib, a selective COX-2 inhibitor, has high gastrointestinal (GI) safety, making it preferable for patients at high risk of GI complications. However, its higher cardiovascular (CV) risk limits its use in patients with cardiovascular problems. Naproxen, a non-selective NSAID, is associated with major gastrointestinal risks, but is favored for its relatively lower cardiovascular risk, especially at lower doses.

Keywords: Ostearthritis, NSAIDs, Prostaglandins, COX-1, COX-2, Gastrointestinal, Cardiovascular.